NCT05961605

Brief Summary

A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2023

Shorter than P25 for all trials

Geographic Reach
1 country

12 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 25, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 27, 2023

Completed
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2023

Completed
Last Updated

August 1, 2023

Status Verified

July 1, 2023

Enrollment Period

3 months

First QC Date

July 25, 2023

Last Update Submit

July 26, 2023

Conditions

Psoriasis PatientsCOVID-19

Keywords

psoriasiscovid-19

Outcome Measures

Primary Outcomes (1)

  • The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection

    The impact of SARS-CoV-2 infection on psoriasis in patients receiving different baseline therapies of psoriasis.

    March 15,2023 to May 30,2023

Secondary Outcomes (1)

  • Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection

    March 15,2023 to May 30,2023

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Psoriasis patients registered in the database from January 2018 to November 2022

You may qualify if:

  • No age limit, both male and female are accepted;
  • Psoriasis patients registered in the database;
  • Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

You may not qualify if:

  • Patients are thought having conditions which are not appropriated for attending this clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

COMPLETED

The First Hospital of Lanzhou University

Lanzhou, Gansu, 730000, China

COMPLETED

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, 510091, China

COMPLETED

The Second Hospital of Jilin University

Changchun, Jilin, 130041, China

COMPLETED

Dalian Dermatosis Hospital

Dalian, Liaoning, 116021, China

COMPLETED

Xining First People's Hospital

Xining, Qinghai, 810000, China

COMPLETED

Xijing Hospital, The Fourth Military Medical University

Xi'an, Shaanxi, 710032, China

RECRUITING

Shanghai Skin Disease Hospital, Tongji University School of Medicine

Shanghai, Shanghai Municipality, 200443, China

COMPLETED

The University of Hong Kong-Shenzhen Hospital

Shenzhen, Shenzhen, 518053, China

COMPLETED

West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

COMPLETED

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

Tianjin, Tianjin Municipality, 300021, China

COMPLETED

People's Hospital of Xinjiang Uygur Autonomous Region，Xinjiang Key Laboratory of Dermatology Research

Ürümqi, Xinjiang, 830001, China

COMPLETED

Related Publications (1)

  • Liu Y, Xu Z, Zhou J, Chen A, Zhang J, Kang X, Jiang X, Lyu C, Shi C, Shi Y, Liu X, Li F, Yang B, Huang Y, Yu C, Wang G. Clinical characteristics and outcomes of psoriasis patients with COVID-19: A retrospective, multicenter cohort study in China. Chin Med J (Engl). 2024 Jul 20;137(14):1736-1743. doi: 10.1097/CM9.0000000000003024. Epub 2024 May 6.

    PMID: 38710539DERIVED

MeSH Terms

Conditions

COVID-19Psoriasis

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesSkin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • GANG WANG, M.D.

    Xijing Hospital, The Fourth Military Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

GANG WANG, M.D.

CONTACT

13571991903xjwgang@fmmu.edu.cn

CHEN YU

CONTACT

13571991903

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Chief Director of Department of Dermatology

Study Record Dates

First Submitted

July 25, 2023

First Posted

July 27, 2023

Study Start

March 15, 2023

Primary Completion

May 30, 2023

Study Completion

July 30, 2023

Last Updated

August 1, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations

CN(12)